This is a working overview of synaptic plasticity, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-02 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
=== Mexico === In Mexico, physicians need to take the ENARM (National Test for Aspirants to Medical Residency) (Spanish: Examen Nacional de Aspirantes a Residencias Médicas) in order to have a chance for a medical residency in the field they wish to specialize. The physician is allowed to apply to only one speciality each year. Some 35,000 physicians apply and only 8000 are selected. The selected physicians bring their certificate of approval to the hospital that they wish to apply (Almost all the hospitals for medical residency are from government based institutions). The certificate is valid only once per year and if the resident decides to drop residency and try to enter a different speciality she will need to take the test one more time (no limit of attempts). All the hosting hospitals are affiliated to a public/private university and this institution is the responsible to give the degree of "specialist". This degree is unique but equivalent to the MD used in the UK and India. In order to graduate, the trainee is required to present a thesis project and defend it. The length of the residencies is very similar to the American system. The residents are divided per year (R1, R2, R3, etc.). After finishing, the trainee may decide if he wants to sub-specialize (equivalency to fellowship) and the usual length of sub-specialty training ranges from two to four years. In Mexico the term "fellow" is not used. All the specialties in Mexico are board certified and some of them have a written and an oral component, making these boards ones of the most competitive in Latin America.
== External links == Brain+Natriuretic+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) BNP and NT-proBNP at Lab Tests Online Human NPPB genome location and NPPB gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P16860 (Natriuretic peptides B) at the PDBe-KB.
Collagen alpha-1(XVIII) chain is a protein that in humans is encoded by the COL18A1 gene. This gene encodes the alpha chain of type XVIII collagen. This collagen is one of the multiplexins, extracellular matrix proteins that contain multiple triple-helix domains (collagenous domains) interrupted by non-collagenous domains. The proteolytically produced C-terminal fragment of type XVIII collagen is endostatin, a potent antiangiogenic protein. Mutations in this gene are associated with Knobloch syndrome. The main features of this syndrome involve retinal abnormalities so type XVIII collagen may play an important role in retinal structure and in neural tube closure. Two transcript variants encoding different isoforms have been found for this gene.
Sources: en.wikipedia.org
In 1147, Roger II attacked Corinth and Thebes, two important centers of Byzantine silk production, capturing the weavers and their equipment and establishing his own silkworks in Calabria, thereby allowing the Norman silk industry to flourish. In 1194, Frederick II took control of the region, after inheriting the Kingdom from his mother Constance, Queen of Sicily. He created a kingdom that blended cultures, philosophy and customs and built several castles, while fortifying existing ones that the Normans had previously constructed. After the death of Frederick II in 1250, Calabria was controlled by the Capetian House of Anjou, under Charles d’Anjou after he was granted the crown of the Sicilian Kingdom by Pope Clement IV. In 1282, under Charles d’Anjou, Calabria became a domain of the newly created Kingdom of Naples, and no longer of the Kingdom of Sicily, after he lost Sicily due to the rebellion of the Sicilian Vespers. During the 14th century, Barlaam of Seminara who became Petrarch's Greek teacher and his disciple Leonzio Pilato, who translated Homer's works for Giovanni Boccaccio. While the cultivation of mulberry was beginning in northern Italy, silk made in Calabria peaked at 50% of European production. As the cultivation of mulberry was difficult in Northern and Continental Europe, merchants and operators used to purchase raw materials in Calabria. The Genoese silk artisans used fine Calabrian silk for the production of velvets.
=== SPAC merger, public listing, and acquisitions (2020–2023) === In October 2020, Hims announced an agreement to become a publicly traded company through a merger with Oaktree Acquisition Corp., a special-purpose acquisition company led by Oaktree Capital Management co-chairman Howard Marks. The transaction closed on January 20, 2021 at a valuation of $1.6 billion, and shares began trading the following day on the New York Stock Exchange. The deal provided the company with about $280 million in proceeds, including $75 million from private placement investors such as Franklin Templeton Investments. In June 2021, Hims & Hers acquired London-based Honest Health Limited, marking its first international acquisition and expanding its United Kingdom operations. The following month, the company acquired the teledermatology platform Apostrophe (YoDerm, Inc.) for potential consideration of up to $200 million. Apostrophe was shut down in 2025.
=== Nickel exposure === Nickel is both naturally abundant – it is the fifth most common element on earth – and widely used in industry and commercial goods. Workplace nickel exposure is common in many industries, and the performance of normal work tasks can result in nickel skin levels sufficient to elicit dermatitis. Within the workplace, individuals may be exposed to significant amounts of nickel, airborne from the combustion of fossil fuels or from contact with tools that are nickel plated. Historically, workplaces where prolonged contact with soluble nickel has been high have shown high risks for allergic contact nickel dermatitis. For example, nickel dermatitis was common in the past among nickel platers. Outbreaks of nickel allergy from consumer goods have been documented throughout the 20th century, with jewelry, stocking suspenders, and metallic buttons on blue jeans each resulting in dermatitis at the point of contact. Nickel can also be present in food and drinking water; ingestion of increased nickel is not associated with systemic allergic disease, but is associated with flare-ups of dermatitis or aggravation of vesicular hand eczema. Similarly, aggravation of dermatitis has been reported in response to nickel-containing surgical implants or dental gear. The risk of an object eliciting nickel allergy is linked to the amount of nickel released by its surface (and not to its total nickel content). Suspected objects can be screened by wiping the surface with a 1% dimethylglyoxime solution that turns pink if more than 0.5 μg/cm2 per week is released by the surface.
Mrs Justice Cheema-Grubb tells Alid: "The murder of Terence Carney was a terrorist act in which you hoped to influence the British government. You hoped to frighten the British people and undermine the freedoms they enjoy." The UK Health Security Agency confirms the number of cases of cryptosporidiosis in south Devon has risen to 46. Sir Paul McCartney has become the first billionaire British musician according to the 2024 Sunday Times Rich List. 18 May South West Water tells residents in most of Brixham, south Devon they no longer have to boil water before drinking it, but continues to advise households in upper Brixham, Hillhead and Kingswear to do so. The Met Office issues a weather warning for severe thunderstorms for Wales, south west England and the West Midlands. A number of people are reported to be isolating on the cruise ship MV Ventura with gastrointestinal symptoms. Technical problems result in customers being unable to use the M&S website and app for several hours. Declassified documents clear the Welsh Guards of any responsibility in the Argentinian Air Force bombing of RFA Sir Galahad on 8 June 1982, leading to the biggest loss of British lives during the Falklands War; some had blamed the Welsh Guards for disobeying orders to leave the ship, where 48 crewmen were killed. 19 May – South West Water apologises after 30 households in south Devon were wrongly told they could stop boiling water. 20 May The results of a public inquiry into the contaminated blood scandal are published.
Sources: en.wikipedia.org
In August 2004, Palatin signed an agreement with King Pharmaceuticals to co-develop bremelanotide in the US and jointly license it outside the US; King paid Palatin $20 million upfront. Palatin conducted Phase II trials of intranasal bremelanotide in both female sexual dysfunction (FSD) and male erectile dysfunction (ED), but these trials were halted by the FDA in 2007, due to increased blood pressure in clinical trial subjects; Palatin stopped development of the intranasal formulation in 2008. Four trials were conducted in ED, the last being a Phase IIb published in 2008. King terminated the co-development agreement shortly after the FDA halted the trials. The drug was then reformulated to be delivered by injection and trials continued in FSD. A phase II dose-finding trial in FSD in which the drug was administered 45 minutes before sex showed promise at the highest dose and only transient signs of high blood pressure; two Phase III trials were launched at the end of 2014. Palatin launched the Phase III trials with bremelanotide administered via an autoinjector. In 2014, Palatin licensed European rights to bremelanotide to Gedeon Richter Plc. for around $10 million, and Palatin received a milestone payment of around $3 million when it started the Phase III trials in the US. In September 2016, Palatin and Gedeon Richter terminated that agreement. In November 2016, Palatin announced results of the Phase III trials, and shortly thereafter began seeking a partner to complete development in the US.
(The Ruthenian part, Subcarpathian Rus, made also an attempt to declare its sovereignty as Carpatho-Ukraine but only with ephemeral success since the area was soon annexed by Hungary.) Although "Henlein and the SdP had become accessories in Hitler's escalating campaign to annex the Sudetenland to the German Reich" by the summer of 1938, the supporters of the SdP supported autonomy within Czechoslovakia rather than annexation into Germany. Contemporary reports of The Times found that there was a "large number of Sudetenlanders who actively opposed annexation", and that the pro-German policy was challenged by the moderates within the SdP as well; according to Wickham Steed, over 50% of Henlein's supporters favoured greater autonomy within Czechoslovakia rather than joining Germany. Sudeten German historian Emil Franzel argues that the mainstream wing of Henlein's party was "not striving for annexation to Germany, but for genuine autonomy", and the majority of negotiators who conducted talks with Hodža and Beneš belonged to the pro-autonomy wing and were unaware of Henlein's agreements with Hitler. Part of the borderland had an ethnic Polish majority and was invaded and annexed by Poland in 1938.
Powell, one of Eddy's biographers, wrote in 1907 that Quimby's son held an almost identical copy, in Quimby's wife's handwriting, of the Quimby manuscript that Eddy had used when teaching Sally Wentworth. It was dated February 1862, eight months before Eddy met Quimby. In July 1904 the New York Times obtained a copy of the Quimby manuscript from Sally Wentworth's son, and juxtaposed passages with Science and Health to highlight the similarities. It also published Eddy's handwritten notes on Quimby's manuscript to show what the newspaper alleged was the transition from his words to hers. Quimby's manuscripts were published in 1921. Eddy's biographers continued to disagree about his influence on Eddy. Bates and Dittemore, the latter a former director of the Christian Science church, argued in 1932 that "as far as the thought is concerned, Science and Health is practically all Quimby," except for malicious animal mesmerism. Robert Peel, who also worked for the church, wrote in 1966 that Eddy may have influenced Quimby as much as he influenced her. Gardner argued in 1993 that Eddy had taken "huge chunks" from Quimby, and Gill in 1998 that there were only general similarities.
=== Breastfeeding and the prosthetic breast === The breasts of a woman are apocrine glands that produce breastmilk with which to feed an infant child. A woman with implanted prosthetic breasts can breastfeed an infant, yet the breast implants can interfere with the breastfeeding function, especially in the case of a woman whose breast augmentation surgery accidentally cut into the nipple-areola complex (NAC) and might either have damaged the lactiferous ducts or damaged the nerves that serve the nipple-areola complex.
For example, the pattern may be 10 press ups, then two minutes rest, 10 press ups, then two minutes rest etc. The ability to recover during an exercise (active recovery), during a training session, and resting between training sessions are all of fundamental importance in strength training. If recovery cannot take place then fatigue may occur leading to worse performance and an increased chance of injury.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.